About 200 reports

  • R&D Progress Research and Development Brief
  • Licensing and Collaboration

IT IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT FOR BORDERLINE PERSONALITY DISORDER.

  • Antipsychotic
  • Mental Health
  • Psychotic Disorder
  • Therapy
  • Otsuka Pharmaceutical Co., Ltd.
  • THE MENNINGER CLINIC ACQUIRED WEINBERGER CLINIC
  • MCLEAN HOSPITAL

The details ##.

  • Ambulatory Care
  • Health Services
  • Hospital
  • Psychotic Disorder
  • World
  • Products and services segmentation (2019)
  • Products and services segmentation (2019)

While there is not one factor that is known to cause these disorders, there are numerous measurable factors that can contribute to the development of these diseases. disorders.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Canada
  • Demand
  • 3.4.2 Forecast Assumptions and Methods: 12-Month Total Prevalence of PTSD

PTSD, alcohol and drug use disorders, and selected mood, anxiety, and personality disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-##.

  • Anxiety Disorder
  • Epidemiology
  • Mental Health
  • Pathology
  • Forecast
  • 5.3 GLOBAL AND HISTORICAL TRENDS
  • 5.1 DISEASE BACKGROUND

The most common comorbidities associated with OUD are psychiatric disorders such as major depression, anxiety, and personality disorders.

  • Opioid
  • Pharmaceutical
  • Therapy
  • United States
  • Forecast
  • 4.2 CLASSIFICATION OR STAGING SYSTEMS
  • 7.5 CLEARER DIAGNOSTIC GUIDELINES

PTSD, alcohol and drug use disorders, and selected mood, anxiety, and personality disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-##.

  • Anxiety Disorder
  • Mental Health
  • Pathology
  • Pharmaceutical
  • Therapy
  • PIPELINE BY KYOWA KIRIN CO LTD, H2 2019
  • PIPELINE BY GILEAD SCIENCES INC, H2 2019

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • Gilead Sciences, Inc.
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SANDOZ

Therapy Area Cardiovascular Central Nervous System Dermatology Ear Nose Throat Disorders Gastrointestinal Genetic Disorders Genito Urinary System And Sex Hormones Hormonal Disorders Infectious Disease Musculoskeletal Oncology Respiratory Women' s Health Immunology No. of Deals

  • Biosimilar
  • Healthcare
  • Medical Biotechnology
  • Pharmaceutical
  • Sandoz Inc.
  • HOVERINK BIOTECHNOLOGIES INC
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY HOVERINK BIOTECHNOLOGIES INC, H1 2019

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Chemotherapy
  • Gastrointestinal Drug
  • Pharmaceutical
  • Therapy
  • Helsinn Group
  • Clinical Trial profile. 168 Trial Title
  • 5. All the trials included are unique trials.

## ## ## ## ## ## ## ## China ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are ta

  • Antipsychotic
  • Cardiovascular Drug
  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • PARTNERSHIPS

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Dermatological Condition
  • Healthcare
  • Pathology
  • Pharmaceutical
  • LEO Pharma A/S
  • Hisamitsu Pharmaceutical and Kyowa Hakko Kirin Sign Commercialization Agreement for HP-3000

ONE UNIT REFERS TO ONE SPECIALTY BED.

  • Hospital
  • Mattress
  • Wound Care
  • East Asia
  • Japan
  • Clinical Trial profile. 35 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Mental Health
  • Psychotic Disorder
  • Therapy
  • Pfizer Inc.
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SANDOZ
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SBI BIOTECH

Article ##.

  • Healthcare
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Kyowa Hakko Kirin Co., Ltd.
  • 3.2 RISK FACTORS AND COMORBIDITIES
  • Risk Factors and Comorbid Conditions Associated with OUD

The most common comorbidities associated with OUD are psychiatric disorders such as major depression, anxiety, and personality disorders.

  • Epidemiology
  • Hospital
  • Opioid
  • United States
  • Forecast
  • 21.5.1 Business Overview
  • IT IS MESENCHYMAL STEM CELLS-BASED INJECTION INDICATED FOR THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

IT IS ALSO DEVELOPING OTHER STEM CELL-BASED PRODUCTS SUCH AS PNEUMOSTEM (INDICATED FOR BORDERLINE PERSONALITY DISORDER) AND NEUROSTEM (INDICATED FOR ##. ##. ## Major Product Offerings Product TEMCELL HS Injection JCR PHARMACEUTICALS: KEY PRODUCT OFFERINGS Description ALZHEIMER' S D

  • Gene Therapy
  • Medical Biotechnology
  • Therapy
  • World
  • Market Size
  • GLOBAL PREMATURE EJACULATION TREATMENT MARKET BY SSRIS 2016-2021 ($ MILLIONS)
  • SSRIS

These drugs find applications in the treatment of anxiety, depression, and personality disorders.

  • Pharmaceutical
  • Therapy
  • World
  • Forecast
  • Eli Lilly & Co.
  • ASSET PURCHASE

Rx PedPRM is to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • M&A
  • Aspen Pharmacare Holdings Limited
  • BREXPIPRAZOLE - DRUG PROFILE

It is in Phase II stage of development for the treatment for borderline personality disorder.

  • Anxiety Disorder
  • Mental Health
  • Pharmaceutical
  • Therapy
  • Tonix Pharmaceuticals Holding Corp.
  • Sep 05, 2019: Evgen Pharma: Agreement for supply of SFX-01 for autism clinical trial
  • Sep 23, 2019: ORYZON presents new data on vafidemstat

Oryzon Genomics Clinical and Product Development vice-president Dr Michael Ropacki said: " The REIMAGINE trial of vafidemstat has now produced positive results in three debilitating psychiatric disorders with high-unmet medical need: ADHD, autism spectrum disorder, and borderli

  • Clinical Trial
  • Hospital
  • Neurological Disorder
  • Neurology
  • Pharmaceutical
  • ORPEA SA: KEY FACTS
  • LEADING COMPANIES

Orpea' s psychiatric clinic facilities provide services for patients with acute mental pathologies, such as mood disorders, anxiety disorders, addiction, overuse or burnout syndromes, chronic fatigue syndrome, fibromyalgia, sleep disorders, eating disorders, b

  • Health Care Provider
  • Health Services
  • Healthcare
  • Western Europe
  • Market Size
  • BREXPIPRAZOLE - DRUG PROFILE

It is in Phase II stage of development for the treatment for borderline personality disorder.

  • Antipsychotic
  • Mental Health
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • ACTIVIOMICS ENTERS INTO RESEARCH AGREEMENT WITH KYOWA HAKKO
  • ACTIVIOMICS EXTENDS RESEARCH AGREEMENT WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Influenza
  • Pharmaceutical
  • United Kingdom
  • hVIVO plc
  • PIPELINE BY COTINGA PHARMACEUTICALS INC, H1 2018
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Hospital
  • Oncology
  • Therapy
  • World
  • AstraZeneca PLC
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H2 2018
  • JOHNSON & JOHNSON

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Product Initiative
  • Apexigen, Inc.
  • SANFORD HEALTH ACQUIRES HEMATECH, DRUG DEVELOPMENT COMPANY

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Health Services
  • Healthcare
  • Pharmaceutical
  • United States
  • Caladrius Biosciences, Inc.
  • JIANGSU HENGRUI MEDICINE CO LTD
  • PIPELINE BY IO BIOTECH APS, H1 2020

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Chemotherapy
  • Lung Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Description

Chapter ## provides an introduction to the report.

  • Therapy
  • United States
  • Demand
  • MAJOR MARKETS
  • Major market segmentation (2019)

The most common services provided are the treatment of schizophrenic and psychotic disorders, mood disorders such as depression, mania and bipolar disorder, anxiety disorders and personality disorders.

  • Addiction Disorder
  • Clinic
  • Mental Health
  • Pathology
  • Canada
  • FUJIFILM FORMS JOINT VENTURE WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • FUJIFILM Holdings Corporation